# NCT02358031 (NCT02358031)

> A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02358031
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer
- Interventions: Pembrolizumab; Cisplatin; Carboplatin; 5-FU; Cetuximab
- Enrollment: 882
- Primary outcome: Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in All Participants
- Primary outcome: Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1
- Primary outcome: Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥20
- Primary outcome: Pembro Combo vs Control: Overall Survival (OS) in All Participants
- Primary outcome: Pembro Combo vs Control: OS in Participants With PD-L1 CPS ≥1
- Primary outcome: Pembro Combo vs Control: OS in Participants With PD-L1 CPS ≥20
- Primary outcome: Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in All Participants
- Primary outcome: Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1
- Primary outcome: Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥20
- Primary outcome: Pembro Mono vs Control: OS in All Participants
- Primary outcome: Pembro Mono vs Control: OS in Participants With PD-L1 CPS ≥1
- Primary outcome: Pembro Mono vs Control: OS in Participants With PD-L1 CPS ≥20

## Commentary we found

- YouTube: 21
- Podcasts: 21
- X threads: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02358031

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02358031", "email": "<work email>"}; the inbox owner confirms by the emailed link.